Related references
Note: Only part of the references are listed.The potential for antibody-dependent enhancement of SARS-CoV-2 infection: Translational implications for vaccine development
Jiong Wang et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV
Jared S. Morse et al.
CHEMBIOCHEM (2020)
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
Qiurong Ruan et al.
INTENSIVE CARE MEDICINE (2020)
Coronavirus Infections-More Than Just the Common Cold
Catharine I. Paules et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
Hussin A. Rothan et al.
JOURNAL OF AUTOIMMUNITY (2020)
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
Calvin J. Gordon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Antiviral activity of ribavirin and favipiravir against human astroviruses
Andrew B. Janowski et al.
JOURNAL OF CLINICAL VIROLOGY (2020)
Clinical trial analysis of 2019-nCoV therapy registered in China
Qi Zhang et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Convalescent plasma as a potential therapy for COVID-19
Long Chen et al.
LANCET INFECTIOUS DISEASES (2020)
First Case of 2019 Novel Coronavirus in the United States
Michelle L. Holshue et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Kimiyasu Shiraki et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
Emmie de Wit et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
Giovanni Caocci et al.
ANNALS OF HEMATOLOGY (2020)
Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis
Omer Gendelman et al.
AUTOIMMUNITY REVIEWS (2020)
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
Vanessa Monteil et al.
CELL (2020)
Could Chloroquine/Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?
Maurizio Guastalegname et al.
CLINICAL INFECTIOUS DISEASES (2020)
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Xueting Yao et al.
CLINICAL INFECTIOUS DISEASES (2020)
Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
Cornelis Smit et al.
CLINICAL PHARMACOKINETICS (2020)
Chloroquine Dosing Recommendations for Pediatric COVID-19 Supported by Modeling and Simulation
Laurens F. M. Verscheijden et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Deja vu: Stimulating open drug discovery for SARS-CoV-2
Sean Ekins et al.
DRUG DISCOVERY TODAY (2020)
Mechanism of baricitinib supports artificial intelligence-predicted testing inCOVID-19 patients
Justin Stebbing et al.
EMBO MOLECULAR MEDICINE (2020)
Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin
Hartmut Derendorf
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
Jacques Fantini et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Lack of antiviral activity of darunavir against SARS-CoV-2
Sandra De Meyer et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Yang Cao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Kai Duan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Wenhao Dai et al.
SCIENCE (2020)
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
Linlin Zhang et al.
SCIENCE (2020)
Coronavirus disease 2019: What we know?
Feng He et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
Jianjun Gao et al.
BIOSCIENCE TRENDS (2020)
Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review
Ajay N. Sharma et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
Philippe Gautret et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)
COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics
Kuldeep Dhama et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Yeming Wang et al.
LANCET (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
The current understanding and potential therapeutic options to combat COVID-19
Venkatesh Pooladanda et al.
LIFE SCIENCES (2020)
Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19
Mingxing Huang et al.
NATIONAL SCIENCE REVIEW (2020)
Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
Cynthia Liu et al.
ACS CENTRAL SCIENCE (2020)
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin et al.
NATURE (2020)
Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States
NATURE MEDICINE (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Jason D. Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Compassionate Use of Remdesivir for Patients with Severe Covid-19
J. Grein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Development of a Large-Scale Cyanation Process Using Continuous Flow Chemistry En Route to the Synthesis of Remdesivir
Tiago Vieira et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2020)
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Ka-Tim Choy et al.
ANTIVIRAL RESEARCH (2020)
The important role of polysaccharides from a traditional Chinese medicine-Lung Cleansing and Detoxifying Decoction against the COVID-19 pandemic
Peng Cao et al.
CARBOHYDRATE POLYMERS (2020)
The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19
Dongdong Wang et al.
PROCESSES (2020)
The clinical course and its correlated immune status in COVID-19 pneumonia
Ruyuan He et al.
JOURNAL OF CLINICAL VIROLOGY (2020)
Challenges of Convalescent Plasma Therapy on COVID-19
Qian Zhao et al.
JOURNAL OF CLINICAL VIROLOGY (2020)
Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
E. Susan Amirian et al.
ONE HEALTH (2020)
Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains
Eriko Padron-Regalado
INFECTIOUS DISEASES AND THERAPY (2020)
Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex
Erik Laurini et al.
ACS NANO (2020)
Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives
Xiao-lei Zhang et al.
ACTA PHARMACOLOGICA SINICA (2020)
Catalytic Asymmetric Synthesis of the anti-COVID-19 Drug Remdesivir
Mo Wang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Danielle Peterson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials
Vaishali M. Patil et al.
LIFE SCIENCES (2020)
Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
Abdo A. Elfiky
LIFE SCIENCES (2020)
In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
Bhumi Shah et al.
LIFE SCIENCES (2020)
Interleukin-6 as a potential biomarker of COVID-19 progression
Zulvikar Syambani Ulhaq et al.
MEDECINE ET MALADIES INFECTIEUSES (2020)
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Brandi N. Williamson et al.
NATURE (2020)
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Laura Riva et al.
NATURE (2020)
Improvement of the C-glycosylation Step for the Synthesis of Remdesivir
Fei Xue et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2020)
Current targeted therapeutics against COVID-19: Based on first-line experience in China
Yue Zhang et al.
PHARMACOLOGICAL RESEARCH (2020)
Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19
Marinella Lauriola et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Fight against novel coronavirus: A perspective of medicinal chemists
Sk Abdul Amin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic
Mark P. Lythgoe et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine
F. S. Sinkeler et al.
NETHERLANDS HEART JOURNAL (2020)
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
Victoria C. Yan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
Andrea J. Pruijssers et al.
CELL REPORTS (2020)
COVID-19 therapy: What weapons do we bring into battle?
Sinara Monica Vitalino de Almeida et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2020)
In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors
Arun Bahadur Gurung
GENE REPORTS (2020)
Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis
Awadhesh Kumar Singh et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2020)
Toxicokinetics of hydroxychloroquine following a massive overdose
Jonathan de Olano et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2019)
Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
Ariane J. Brown et al.
ANTIVIRAL RESEARCH (2019)
High-yielding continuous-flow synthesis of antimalarial drug hydroxychloroquine
Eric Yu et al.
BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY (2018)
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
Maria L. Agostini et al.
MBIO (2018)
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo(2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
Dustin Siegel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation
Ralf L. J. Schmidt et al.
SCIENTIFIC REPORTS (2017)
T-705 (Favipiravir) suppresses tumor necrosis factor a production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug
T. Tanaka et al.
ACTA VIROLOGICA (2017)
Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis
Amelie Seguin et al.
CHEST (2016)
Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014
Chang-Qing Bai et al.
CLINICAL INFECTIOUS DISEASES (2016)
Coronaviruses - drug discovery and therapeutic options
Alimuddin Zumla et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model
Stuart D. Dowall et al.
JOURNAL OF GENERAL VIROLOGY (2015)
Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis
Chul Won Jung et al.
LEUKEMIA & LYMPHOMA (2015)
Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation
Jia Xue et al.
IMMUNITY (2014)
Discovery of the First C-Nucleoside HCV Polymerase Inhibitor (GS-6620) with Demonstrated Antiviral Response in HCV Infected Patients
Aesop Cho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Yousuke Furuta et al.
ANTIVIRAL RESEARCH (2013)
Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model
Yiwu Yan et al.
CELL RESEARCH (2013)
Comprehensive review of JAK inhibitors in myeloproliferative neoplasms
Mohamad Bassam Sonbol et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
Synthesis and characterization of 2′-C-Me branched C-nucleosides as HCV polymerase inhibitors
Aesop Cho et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides
Aesop Cho et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
New developments in HCV therapy
B. Kronenberger et al.
JOURNAL OF VIRAL HEPATITIS (2012)
Into the Eye of the Cytokine Storm
Jennifer R. Tisoncik et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2012)
Practical synthesis of 1′-substituted Tubercidin C-nucleoside analogs
Sammy E. Metobo et al.
TETRAHEDRON LETTERS (2012)
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses
Maki Kiso et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture
Aartjan J. W. Te Velthuis et al.
PLOS PATHOGENS (2010)
Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains
Neal K. Williams et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Expert opinion on the treatment of patients with chronic hepatitis C
S. Zeuzem et al.
JOURNAL OF VIRAL HEPATITIS (2009)
Assembly of 4-aminoquinolines via palladium catalysis:: A mild and convenient alternative to SNAr methodology
Brandon J. Margolis et al.
JOURNAL OF ORGANIC CHEMISTRY (2007)
In vitro inhibition of human influenza A virus replication by chloroquine
Eng Eong Ooi et al.
VIROLOGY JOURNAL (2006)
Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities
C Biot et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
F Li et al.
SCIENCE (2005)
Programmed ribosomal frameshifting in decoding the SARS-CoV genome
PV Baranov et al.
VIROLOGY (2005)
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Martin J. Vincent et al.
VIROLOGY JOURNAL (2005)
Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity
F Romanelli et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro
G Migliaccio et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs
SS Carroll et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
In vitro and in vivo activities of anti-influenza virus compound T-705
Y Furuta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Share Paper
